Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism (for children under 1 year of age)

Description

Normal
0

false
false
false

EN-US
X-NONE
X-NONE

MicrosoftInternetExplorer4

This study is a
randomized, double-blind, placebo-controlled study that will evaluate the
safety and efficacy of dasiglucagon in children between the ages of 7 days and
12 months who have congenital hyperinsulinism. Dasiglucagon will be given as a
subcutaneous infusion while patients are admitted to the hospital. Other
treatments for hyperinsulinism may be changed as allowed while maintaining safe
blood sugar levels. For the second part of the study, patients may be able to
go home on the medication.

For More Information

Contact Us Online

Call (267) 426-6846


Related Centers and Programs